LeapZipBlog: Steve Blade's blog: Hyoscine-N-Butyl Bromide Market Provides an In-Depth Insight of Sales and Trends, Forecast 2018-2027

Hyoscine-N-Butyl Bromide Market Provides an In-Depth Insight of Sales and Trends, Forecast 2018-2027

August 22, 2019 by Steve Blade  

According to the latest study by Fact.MR, the Hyoscine-N-Butyl Bromide market is expected to bring in more than US$ 50 million in 2019. The study opines that growing prevalence of irritable bowel syndrome (IBS) will continue to underpin hyoscine-N-butyl bromide sales. Over the past few years, the prevalence of IBS and abdominal pain as the gastrointestinal tract disorder has increased, resulting in the increasing consumption of anti-spasmodic drugs. IBS has emerged as one of the most common causes of abdominal pain in the last few years, according to the International Foundation for Gastrointestinal Disorders, the prevalence of IBS is estimated around 10-15% globally.

For Additional Insights on the Key Dynamics Influencing Market Request Sample:   

https://www.factmr.com/connectus/sample?flag=S&rep_id=3269

Table of Content

. Global Hyoscine-N-Butyl Bromide Market - Executive Summary

2. Global Hyoscine-N-Butyl Bromide Market Overview
     2.1. Introduction
            2.1.1. Global Hyoscine-N-Butyl Bromide Market Taxonomy
            2.1.2. Global Hyoscine-N-Butyl Bromide Market Definition
     2.2. Global Hyoscine-N-Butyl Bromide Market Size (US$ Mn) and Forecast, 2013-2027
            2.2.1. Global Hyoscine-N-Butyl Bromide Market Y-o-Y Growth
     2.3. Global Hyoscine-N-Butyl Bromide Market Dynamics
     2.4. Supply Chain
     2.5. Cost Structure
     2.6. Pricing Analysis 
     2.7. Raw Material Sourcing Strategy and Analysis
     2.8. Service Provider List
     2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Hyoscine-N-Butyl Bromide Market Analysis and Forecast 2013-2027 
     3.1. Global Hyoscine-N-Butyl Bromide Market Size and Forecast By Application, 2013-2027
            3.1.1. Oral Market Size and Forecast, 2013-2027
                     3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                     3.1.1.2. Market Share Comparison, By Region
                     3.1.1.3. Y-o-Y growth Comparison, By Region
            3.1.2. Injectables Market Size and Forecast, 2013-2027
                     3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                     3.1.2.2. Market Share Comparison, By Region
                     3.1.2.3. Y-o-Y growth Comparison, By Region

4. North America Hyoscine-N-Butyl Bromide Market Size and Forecast, 2013-2027
     4.1. Revenue (US$ Mn) Comparison, By Country 
     4.2. Revenue (US$ Mn) Comparison, By Application 

To be Continue........

Oral Hyoscine-N-Butyl Bromide to Find Increasing Demand

Hyoscine-N-Butyl Bromide used to treat abdominal pain and spasms is available in both oral and injectable form. However, with increasing sales of Hyoscine-N-Butyl Bromide under the brandname Buscopan which is an oral medication, the application of Hyoscine-N-Butyl Bromide in oral form is gaining traction. Moreover, with a range of benefits on oral administration of Hyoscine-N-Butyl Bromide, it is being used on a large scale. Upon oral administration, it binds and blocks muscarinic receptors, thereby, providing anti-spasmodic effect in the uterine, gastrointestinal, and urinary tracts. 

Many oral analgesic drugs are also finding wide application to relieve pain during gynecological procedures. Hyoscine-N-Butyl Bromide has gained popularity as the oral anti-spasmodic drug for relief from genito-urinary spasms.   

Hyoscine-N-Butyl Bromide Market: Assessment of Competitive Landscape

  • Boehringer Ingelheim has filed for the regulatory approval of Nintedanib for patients with systemic sclerosis associated interstitial lung disease with the EMA and FDA. Recently, Boehringer also entered into a research collaboration with GNA Biosolutions to develop emergency veterinary diagnostics, including rapid diagnostic test for African swine fever that can be used on the portable molecular diagnostic platform by GNA.
  • The FDA has approved Dicyclomine HCl Injection, the generic version of Bentyl Injection by Aptalis Pharma. Dicyclomine HCl is an anti-spasmodic and anti-cholinergic agent that helps to relieve smooth muscle spasms in the gastrointestinal tract. The injection is supplied as 20mg/2ml.
  • Recently, the meta-analysis that was undertaken to evaluate effectiveness of the IBS treatment options, noted three clinical studies that have shown Buscopan as more effective in relieving IBS symptoms as compared to placebo. The clinical studies have also found minimal side-effects of Buscopan. Currently, Buscopan is rarely prescribed in the US, however, it may be commonly prescribed by physicians outside the US.

Have Any Query?? Ask Our Industry Expert:  https://www.factmr.com/connectus/sample?flag=AE&rep_id=3269

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

sales@factmr.com

www.factmr.com